Dr. Den Discusses Bone Metastases in Prostate Cancer

Robert B. Den, MD
Published: Wednesday, Apr 04, 2018



Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone metastases in prostate cancer.

Prostate cancer is a unique malignancy, as it tends to have a preponderance of metastases to the bone. Bone metastases can impact a patient’s quality of life by causing severe bone pain, which is an area where investigators have been looking into targeting the bone microenvironment specifically.

Commonly used bone-targeted agents for the treatment of patients with metastatic castration-resistant prostate cancer include zoledronic acid (Zometa), denosumab (Xgeva), and radium-223 dichloride (Xofigo). These agents are designed to target the makeup of the bone, Den explains.


Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone metastases in prostate cancer.

Prostate cancer is a unique malignancy, as it tends to have a preponderance of metastases to the bone. Bone metastases can impact a patient’s quality of life by causing severe bone pain, which is an area where investigators have been looking into targeting the bone microenvironment specifically.

Commonly used bone-targeted agents for the treatment of patients with metastatic castration-resistant prostate cancer include zoledronic acid (Zometa), denosumab (Xgeva), and radium-223 dichloride (Xofigo). These agents are designed to target the makeup of the bone, Den explains.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x